CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
autologous IKDC-like cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02661685
NCT02661685Phase 1Completed
CompareCT.gov

An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial

National Defense Medical Center, Taiwan·interventional·Posted Jan 22, 2016·Updated Feb 18, 2021

In Brief

A Phase 1 clinical trial evaluating autologous IKDC-like cells for Neoplasm Metastasis. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety of adoptive transferring autologous IKDC-like cells

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm Metastasis
CountriesTaiwan
CollaboratorsMinistry of Science and Technology, Taiwan, Academia Sinica, Taiwan

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 22, 2016
Enrollment StartMay 1, 2016
Primary CompletionOct 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.4 years ago

Interventions

autologous IKDC-like cellsbiological

Subject received autologous IKDC-like cells every 14 days